A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: HP518 - Dose EscalationDrug: HP518 - Dose expansion
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Hinova Pharmaceuticals Aus Pty Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT05252364
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Border Medical Oncology, Albury, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath